Back to News
Market Impact: 0.3
Merck's KEYTRUDA QLEX Approved In Japan For Subcutaneous Use
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Japan's Ministry of Health, Labor and Welfare approved Merck's KEYTRUDA QLEX, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph. The approval expands Merck's oncology treatment-administration options in Japan and could support KEYTRUDA franchise convenience and adoption.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
MRK0.65
More News
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros
- Canada’s BC sues OpenAI over ChatGPT role in Tumbler Ridge school shooting
- Paramount settles lawsuit blocking $110 billion Warner Bros. merger
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Build an Automated Research Process for a Fund
- Weekly Update: AI-Powered Report Editing, Investor Relations, and Enhanced Search